Umbilical Cord Derived Mesenchymal Stem Cells for Treatment-induced Myelosuppression in Hematologic Malignancies

Anemia Clinical Trial

Official title:

A Multicenter, Phase Ib/II Trial of the Safety and Efficacy of Umbilical Cord Derived Mesenchymal Stem Cells in Treatment-induced Myelosuppression in Patients With Hematologic Malignancies (USMYE Trial)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05672420
• Other study ID #: UHCT22668
• Status: Not yet recruiting
• Phase: Phase 1/Phase 2
• Start date: January 1, 2023
• Est. completion date: January 31, 2025

Study information

• Verified date: January 2023
• Source: Wuhan Union Hospital, China
• Contact: Qiubai Li, Professor
• Phone: (027) 85726387
• Email: qiubaili[@]hust.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to explore the safety and efficacy of umbilical cord derived mesenchymal stem cells in treatment-induced myelosuppression in patients with hematologic malignancies.

Description:

Despite the improved prognosis of patients with hematologic malignancies, almost all patients will experience severe myelosuppression induced by anti-cancer treatment, leading to a series of complications such as infection due to neutropenia, bleeding due to thrombocytopenia and/or impaired major organ function such as cardiac function due to anemia, which are the main reasons for dose reduction, dose interrruptions of anti-cancer treatment, failure of hematopoietic stem cell transplantation, and also patients' treatment-related death. It is of significant clinical importance and an urgent need to promote early recovery of myelosuppression and reduce risks of related complications as well as medical burdens. Umbilical cord derived mesenchymal stem cells (UC-MSCs), as a kind of stem cells with multipotential, can widely act on the functional cell units of bone marrow microenvironment and promote the repairment and regeneration of key cells such as hematopoietic stem cells, mesenchymal stem cells and endothelial cells, thus making it an ideal means for effectively promoting recovery of myelosuppression. Patients with hematologic malignancies and treatment-induced myelosuppression will be invited to participate in the Phase Ib/II study, to receive UC-MSCs intravenous infusion and follow-up visits of up to 2 years after enrollment.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 181
• Est. completion date: January 31, 2025
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Aged between 18 and 75 years old;

2. Either type of primary hematologic malignancies listed below:

1. Acute myeloid leukemia (AML, AML subtype M3 excluded) or acute lymphoblastic leukemia (ALL) diagosed according to the 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia, either treatment naive participants who are going to receive first induction therapy, or participants who failed first induction therapy and are going to receive re-inducton therapy;

2. AML or ALL participants who achieved remission and are going to receive consolidation therapy;

3. Relapsed/refractory AML or ALL participants who are going to receive first re-induction therapy;

4. Phase II trial will also include: participants with primary hematological maligancies who are going to receive autologous hematopoietic stem cell transplantation (allo-HSCT) whereas are poor mobilizers (CD34+cell count in peripheral blood was below 11-19/µL before collection, or the amount of CD34+ cells transfused was below 2×10^6/kg in allo-HSCT), and the participants' peripheral superficial veins have smooth blood flow which can meet the demand for intravenous drip;

3. The participant or his/her legal guardian is adequately informed of the nature and risks of the study, voluntarily participates in the study with signed informed consent;

4. Male or female;

5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2 (by the day anti-cancer therapy is initiated)

6. Estimated survival of at least 3 months;

7. Adequate major organ function:

1. Respiratory function: indoor oxygen saturation of at least 95%;

2. Cardiac function: ejection fraction of left ventricular of at least 45%;

3. Hepatic function: alanine aminotransferase/aspartate aminotransferase of at most 2.5 times/upper limit of normal value and serum total bilirubin of at most 1.5 times/upper limit of normal value;

4. Renal function: Serum creatinine of at most 1.5 times/upper limit of normal value;

8. Participants who do not receive any type of anti-cancer therapy within 2 weeks before enrollment (radiation therapy, chemotherapy and/or immune therapy, et al.), and treatment-associated toxicities induced by previous therapy has recovered to Grade 1 or below (except for low grade toxities such as alopecia).

Exclusion Criteria:

1. Overt central nervous system manifestations of hematologic malignancies at diagnosis;

2. Secondary hematological maligancies;

3. Body mass index (BMI) of more than 30 kg/m^2;

4. Myelosuppression induced by conditions other than anti-cancer therapy;

5. Previous radiation therapy performed on sternum or pelvis;

6. Specifically diagnosed and uncontrolled infection at enrollment (Uncontrolled is defined as exhibiting ongoing signs and symptoms of infection without improvement despite anti-infective agents) ;

7. Uncontrolled active bleeding at enrollment;

8. Severe underlying comorbidities affecting survival, including cachexia, severe malnutrition, etc;

9. Estimated survival of at most 48 hours;

10. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection;

11. History of or current human immunodeficiency virus (HIV) infection;

12. Continuous usage of immunosuppressants or received organ transplantation in the last 6 months;

13. Participation in clinical trials of other drugs within 6 weeks before enrollment;

14. Previous participation in clinical stem cell research;

15. Receiving any agent concurrently with UC-MSCs infusion which inhibits cell division (hydroxyurea, low-dose cytarabine or methotrexate, etc) ;

16. Severe allergic constitution, or known or suspected allergy to the study drug and its components;

17. Known contraindication to receiving hematopoietic growth factors, transfusion of blood components, anti-infective agents;

18. Female participants who are pregnant or breast feeding;

19. Participants with fertility plan;

Note: For female participants, they should be surgical sterilized or post-menopausal, or agree to utilize a medically recognised method of contraception (such as intrauterine device, condom) during treatment period of the study and within 6 months after the end of treatment period of the study; For male participants, they should be surgical sterilized or agree to utilize a medically recognised method of contraception (such as intrauterine device, condom) during treatment period of the study and within 6 months after the end of treatment period of the study;

20. Participants suffering from mental illness;

21. Presence of drug abuse/addiction;

22. History of other malignancies other than hematological malignancies within 3 years;

23. Participants without signed informed consent;

24. Participants with poor compliance and are unable to complete the whole course of the study;

25. Participants with circumstances that, in the opinion of the investigator, may increase the risk of the participants or interfere with conduct of the clinical trial and the judgment of results (excessive tension, sensitivity or cognitive impairment, etc) ;

26. Participants with other circumstances that are ineligible for enrollment in this study, in the opinion of the investigator.

Related Conditions & MeSH terms

• Anemia
• Bleeding
• Hematologic Neoplasms
• Hemorrhage
• Infections
• Neoplasms
• Neutropenia
• Thrombocytopenia

Intervention

Biological:
• umbilical cord derived mesenchymal stem cells
umbilical cord derived mesenchymal stem cells, intravenous infusion

Locations

Country	Name	City	State
China	Wuhan Central Hospital	Wuhan	Hubei
China	Wuhan Tongji Hospital	Wuhan	Hubei
China	Wuhan Union Hospital	Wuhan	Hubei

Sponsors (3)

Lead Sponsor	Collaborator
Wuhan Union Hospital, China	Wuhan Central Hospital, Wuhan TongJi Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose-limiting toxicities(DLT)	During the DLT observation period, the subject has an adverse event that is reasonably related to UC-MSCs infusion (possibly, likely or definitely related).	4 days after the last UC-MSCs dose, up to 12 days
Primary	Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)	To investigate the safety characteristics, percentages will be calculated and grade will be evaluated.	From the day that the last UC-MSCs dose is used to up to 21 days
Primary	Maximum tolerated dose (MTD)	During the dose-escalation phase, the highest dose of dose-limiting toxicity for subjects less than or equal to 1/3 in the dose group of at least 6 evaluble subjects of the study drug after the last UC-MSCs dose.	From the day that the last UC-MSCs dose is used to up to 4 days
Secondary	Time to absolute neutrophil count recovery	To investigate the efficacy characteristics, time will be measured in days.	From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
Secondary	Incidence of febrile neutropenia	To investigate the efficacy characteristics, percentages will be calculated.	From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
Secondary	Duration of febrile neutropenia	To investigate the efficacy characteristics, the duration will be measured in days.	From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
Secondary	Incidence of severe thrombocytopenia	To investigate the efficacy characteristics, percentages will be calculated.	From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
Secondary	Time to severe thrombocytopenia recovery	To investigate the efficacy characteristics, time will be measured in days.	From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
Secondary	Incidence of severe anemia	To investigate the efficacy characteristics, percentages will be calculated.	From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
Secondary	Time to severe anemia recovery	To investigate the efficacy characteristics, time will be measured in days.	From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
Secondary	Incidence of infetion	To investigate the efficacy characteristics, percentages will be calculated.	From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
Secondary	Duration of infetion	To investigate the efficacy characteristics, the duration will be measured in days.	From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
Secondary	Incidence of bleeding	To investigate the efficacy characteristics, percentages will be calculated.	From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
Secondary	Duration of bleeding	To investigate the efficacy characteristics, the duration will be measured in days.	From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
Secondary	Application rate of blood transfusion	To investigate the efficacy characteristics, percentages will be calculated.	From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
Secondary	Application rate of anti-infective agents	To investigate the efficacy characteristics, percentages will be calculated.	From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
Secondary	Time to achievement of complete remission	To investigate the efficacy characteristics, time will be measured in days.	From enrollment to up to 28 days
Secondary	Duration of complete remission	To investigate the safety characteristics, the duration will be measured in days or months.	From enrollment to maximun up to 2 years
Secondary	Event free survival	From enrollment to the day of any event.	From enrollment to maximun up to 2 years
Secondary	Overall survival	From enrollment to the day of death caused by any reason.	From enrollment to maximun up to 2 years
Secondary	Incidence of infusion reactions in 2 years	To investigate the safety characteristics, percentages will be calculated.	2 years since the last UC-MSCs infusion
Secondary	Incidence of secondary tumor in 2 years	To investigate the safety characteristics, percentages will be calculated.	2 years since the last UC-MSCs infusion
Secondary	Cumulative incidence of relapse of primary disease in 2 years	To investigate the safety characteristics, percentages will be calculated.	2 years since the last UC-MSCs infusion